share_log

Huaxia Eye Hospital GroupLtd's (SZSE:301267) Soft Earnings Don't Show The Whole Picture

Huaxia Eye Hospital GroupLtd's (SZSE:301267) Soft Earnings Don't Show The Whole Picture

华夏眼科医院集团有限公司(SZSE:301267)的业绩不佳并不能展示全部情况
Simply Wall St ·  11/04 16:01

The most recent earnings report from Huaxia Eye Hospital Group Co.,Ltd. (SZSE:301267) was disappointing for shareholders. Despite the soft profit numbers, our analysis has optimistic about the overall quality of the income statement.

华夏眼科医院集团有限公司(SZSE:301267)最新的收益报告令股东们失望。尽管利润数字不佳,但我们的分析对于财务报表的整体质量持乐观态度。

big
SZSE:301267 Earnings and Revenue History November 5th 2024
SZSE:301267盈利和营业收入历史2024年11月5日

How Do Unusual Items Influence Profit?

非常规项目如何影响利润?

Importantly, our data indicates that Huaxia Eye Hospital GroupLtd's profit was reduced by CN¥123m, due to unusual items, over the last year. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner rather than later. We looked at thousands of listed companies and found that unusual items are very often one-off in nature. And that's hardly a surprise given these line items are considered unusual. If Huaxia Eye Hospital GroupLtd doesn't see those unusual expenses repeat, then all else being equal we'd expect its profit to increase over the coming year.

重要的是,我们的数据显示,华夏眼科医院集团有限公司的利润今年因飞凡项目减少了人民币12300万。看到飞凡项目影响公司利润并不是好事,但好消息是,情况可能会变得更好。我们研究了成千上万家上市公司,发现飞凡项目往往是一次性的。鉴于这些项目被认为是不寻常的,这并不奇怪。如果华夏眼科医院集团有限公司不再出现这些不寻常的费用,其他条件相同的情况下,我们预计其利润将在未来一年内增加。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

这可能会让您想知道分析师对未来盈利能力的预测。幸运的是,您可以单击此处查看基于其估计的未来盈利能力的互动图表。

Our Take On Huaxia Eye Hospital GroupLtd's Profit Performance

我们对华夏眼科医院集团有限公司的利润表现的看法

Because unusual items detracted from Huaxia Eye Hospital GroupLtd's earnings over the last year, you could argue that we can expect an improved result in the current quarter. Based on this observation, we consider it likely that Huaxia Eye Hospital GroupLtd's statutory profit actually understates its earnings potential! And on top of that, its earnings per share have grown at 5.9% per year over the last three years. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. If you want to do dive deeper into Huaxia Eye Hospital GroupLtd, you'd also look into what risks it is currently facing. Case in point: We've spotted 1 warning sign for Huaxia Eye Hospital GroupLtd you should be aware of.

由于飞凡项目在华夏眼科医院集团Ltd的收入中扣除了过去一年的收益,因此我们可以预期当前季度有所改善。根据这一观察,我们认为华夏眼科医院集团Ltd的财务利润实际上低估了其盈利潜力!而且,其每股收益在过去三年中以5.9%的速度增长。本文的目标是评估我们能否依靠财务利润来反映该公司的潜力,但还有很多要考虑的其他因素。如果您想深入了解华夏眼科医院集团Ltd,您还应该了解它目前面临的风险。举例来说:我们发现了一项警示信号,提醒您需要留意的。

This note has only looked at a single factor that sheds light on the nature of Huaxia Eye Hospital GroupLtd's profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.

这则说明只看了一个能够揭示华夏眼科医院集团Ltd利润性质的因素。但有许多其他方式可以帮助您了解公司。一些人认为,高股本回报率是优质企业的好迹象。尽管这可能需要您进行一些研究,您可能会发现这份免费的高股本回报率公司收集,或者这份持有大量内部持股的股票清单对您有所帮助。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧吗?请直接与我们联系。或者,发送电子邮件至editorial-team @ simplywallst.com。
Simply Wall St的这篇文章是一般性质的。我们仅基于历史数据和分析师预测提供评论,使用公正的方法,我们的文章并非意在提供财务建议。这并不构成买入或卖出任何股票的建议,并且不考虑您的目标或财务状况。我们旨在为您带来基于基础数据驱动的长期聚焦分析。请注意,我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St对提及的任何股票都没有持仓。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发